Related references
Note: Only part of the references are listed.Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
William H. D. Hallett et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κB activation in blasts in myelodysplastic syndromes
Asaka Kondo et al.
BLOOD (2010)
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
Qing Zhou et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Multiple myeloma: biology of the disease
Anuj Mahindra et al.
BLOOD REVIEWS (2010)
A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients
Klaudia Kuranda et al.
EXPERIMENTAL HEMATOLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis
Yuhuan Zheng et al.
BLOOD (2009)
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma
Ryo Yamamoto et al.
CANCER SCIENCE (2009)
Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Thishi Yamashita et al.
CLINICAL CANCER RESEARCH (2009)
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
R. A. Kyle et al.
LEUKEMIA (2009)
Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes
Chikako Satoh et al.
LEUKEMIA RESEARCH (2009)
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
Takeshi Azuma et al.
BLOOD (2008)
Interaction of human PD-L1 and B7-1
Manish J. Butte et al.
MOLECULAR IMMUNOLOGY (2008)
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Teru Hideshima et al.
NATURE REVIEWS CANCER (2007)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
CD28-mediated regulation of multiple myeloma cell proliferation and survival
Nizar J. Bahlis et al.
BLOOD (2007)
The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions
Constantine S. Mitsiades et al.
EUROPEAN JOURNAL OF CANCER (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia
H Tamura et al.
CLINICAL CANCER RESEARCH (2005)
International staging system for multiple myeloma
PR Greipp et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells
F Silvestris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing δ/λ type immunoglobulin
Y Matsuo et al.
LEUKEMIA RESEARCH (2004)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction
SD Wang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Immunology of H7-H1 and its roles in human diseases
H Tamura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2003)
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism
Y Dai et al.
BLOOD (2002)
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway
M Chatterjee et al.
BLOOD (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Role of Bcl-2 family of proteins in malignancy
BC Baliga et al.
HEMATOLOGICAL ONCOLOGY (2002)
B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function
H Tamura et al.
BLOOD (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
